Cellular and gene therapy for major histocompatibility complex class II deficiency

Area of Science:

• Immunology
• Genetics
• Gene Therapy

Background:

• Major histocompatibility complex (MHC) class II deficiency is a severe primary immunodeficiency.
• This condition impairs the adaptive immune system's ability to recognize and respond to pathogens.

Purpose of the Study:

• To evaluate the efficacy of lentiviral vectors for gene therapy in a mouse model of MHC class II deficiency.
• To develop and optimize a direct genetic correction diagnostic test for identifying specific gene defects in MHC II-deficient patients.

Main Methods:

• Utilized lentiviral vectors for gene delivery in a preclinical mouse model.
• Developed a genetic correction approach to create a diagnostic assay.
• Applied the diagnostic test to identify defective MHC II genes in patients.

Main Results:

• Successful application of lentiviral vectors demonstrated potential for gene therapy in MHC class II deficiency.
• Optimized a diagnostic test enabling precise identification of the causative genetic defect in patients.
• The diagnostic test can distinguish between defects in the four distinct MHC II genes.

Conclusions:

• Lentiviral vector gene therapy shows promise for treating MHC class II deficiency.
• The optimized diagnostic test is crucial for accurate patient diagnosis and personalized treatment strategies.
• Advancements in gene therapy and diagnostics offer new hope for individuals with primary immunodeficiencies.